Publication at First Faculty of Medicine |
2023
Abstract
The group of HER2-negative breast cancers differs not only by the expression of hormone receptors but currently also by the level of HER2 (human epidermal growth factor receptor 2) expression. The newly introduced term HER2-low breast cancer includes tumors immunohistochemically classified as HER2 1+ or 2+/ ISH (in situ hybridization) negative.
With the development of antibody conjugates with a higher generration cytostatic, the possibility of targeted anti-HER2 therapy opens up in a large subset of HER2-low tumors. The aim of the paper is to present the results of phase III clinical trial DESTINY-Breast04 with trastuzumab deruxtecan in the therapy of pre-treated patients with HER2-low metastatic breast cancer.